Source: International Congress 2016 – IPF pathogenesis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Aurélien Justet (Villemomble, France), Aurélien Justet, Raphael Borie, Hilario Nunes, Vincent Cottin, Sylvain Marchand Adam, Jacques Cadranel, Emmanuel Bergot, Lidwine Wemeau-Stervineau, Jean Marc Naccache, Eline Magois, Irene Frachon, Anne Gondouin, Anas Medhaoui, Jean Francois Cordier, Dominique Valeyre, Bernard Grandchamp, Caroline Kanengiesser, Bruno Crestani. Safety and efficacy of pirfenidone in patients with lung fibrosis and TERT mutation. Eur Respir J 2016; 48: Suppl. 60, 484

Member's Comments

No comment yet.

Related content which might interest you: Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation Source: Eur Respir J, 57 (2) 2003198; 10.1183/13993003.03198-2020 Year: 2021 Nintedanib (BIBF 1120) prevents TGF-beta-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function Source: Eur Respir J 2016; 48: 843-851 Year: 2016 Effect of baseline statin use on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Pirfenidone post-authorization safety registry (PASSPORT) update Source: International Congress 2015 – Treatment of IPF Year: 2015